Trial · NCT00856492
Results by group252
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 252
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Pathological Complete Response Rate | Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 35 | Participants | ||
| Number of Patients With Pathological Complete Response Rate | Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)) | 24 | Participants | ||
| Overall Survival | Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 14 | deaths | ||
| Overall Survival | Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)) | 17 | deaths | ||
| Event-free Survival | Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | 20 | participants | ||
| Event-free Survival | Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)) | 24 | participants | ||
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | Abdominal pain | 2 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm II (Nab-Paclitaxel - AC+PEG-G) | Abdominal pain | 0 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm III (AC+PEG-G - Nab-Paclitaxel) | Abdominal pain | 0 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | Adult respiratory distress syndrome | 1 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm II (Nab-Paclitaxel - AC+PEG-G) | Adult respiratory distress syndrome | 0 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm III (AC+PEG-G - Nab-Paclitaxel) | Adult respiratory distress syndrome | 0 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | Alanine aminotransferase increased | 2 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm II (Nab-Paclitaxel - AC+PEG-G) | Alanine aminotransferase increased | 2 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm III (AC+PEG-G - Nab-Paclitaxel) | Alanine aminotransferase increased | 1 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | Anemia | 13 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm II (Nab-Paclitaxel - AC+PEG-G) | Anemia | 6 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm III (AC+PEG-G - Nab-Paclitaxel) | Anemia | 13 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) | Anorectal infection | 2 | Participants | |
| Number of Adverse Events That Are Possibly, Probably or Definitely Related to Study Drug | Arm II (Nab-Paclitaxel - AC+PEG-G) | Anorectal infection | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00856492/results